Pfizer to acquire Array BioPharmaPfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. Dr. Reddy’s to sell neurology branded products to Upsher-SmithDr. Reddy’s is selling the U.S. and select territory rights for Zembrace Symtouch and Tosymra to Upsher-Smith Labs for an upfront price of $70 million and $40.5 million in milestone and other considerations. Merck to acquire Tilos Therapeutics Tilos Therapeutics develops products for the treatment of cancer, fibrosis and autoimmune diseases. Ironshore Pharmaceuticals launches Jornay PM Jornay PM is the first and only ADHD stimulant medication that is dosed in the evening to improve and control symptoms throughout the day. FDA approves 2 new indications for Merck's Keytruda With the FDA's latest approval, Merck's Keytruda is now a therapeutic option for patients with head and neck cancer. GSK gets FDA nod for 2 methods of administering Nucala Nucala is the first anti-IL5 biologic to be licensed in the United States for at-home administration and the first respiratory biologic to be approved for administration via an autoinjector. Exeltis USA get FDA nod for Slynd birth control Slynd is the first and only progestin-only pill for pregnancy prevention with a 24/4 dosing regimen and 24-hour missed pill window. FDA approves new indication for Lilly’s Emgality Emgality is the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache. Upsher-Smith receives two DIANA awards, expands its HQ Upsher-Smith received two Healthcare Distribution Alliance DIANA awards as it celebrated a nearly 300,000-sq.-ft. expansion of its headquarters. AbbVie gets FDA nod for Venclexta combination treatment Venclexta (venetoclax) in combination with obinutuzumab (Gazyva) provides a chemotherapy-free combination treatment option. First Previous 37 38 39 40 41 Next Last
